ImmunityBio, Inc.

IBRX Nasdaq SEC CIK 1326110
Follow ImmunityBio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $48.8M +52.3% vs same quarter last year
Net income −$184.6M −174.4% vs same quarter last year
EPS, diluted −$0.18 −157.1% vs same quarter last year
Operating cash flow −$75.3M −9.3% vs same quarter last year
Revenue by quarter
$7.6M
$16.5M
$26.4M
$32.1M
$38.3M
$44.2M
$51.2M
$48.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$113.3M−$351.5M
FY24$14.7M−$413.6M
FY23$622K−$583.9M
FY22$240K−$417.3M
FY21$934K−$349.8M
FY20$605K−$221.9M
FY19$2.2M−$157.8M
FY18$47K−$96.2M
FY17$45K−$96.4M
FY16$44K−$120.8M
FY15$236K−$236.9M
FY14$641K−$6.2M
FY13$600K−$2M
FY12--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300000%−200000%−100000%0%100000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2599.3%−226%−310.3%
FY24100%−2334.2%−2805%
FY23100%−58239.5%−93874.6%
FY22100%−146374.2%−173875%
FY21-−35361.9%−37451.8%
FY20-−36509.1%−36669.6%
FY19-−7095.9%−7165.2%
FY18-−209338.3%−204736.2%
FY17-−220266.7%−214273.3%
FY16-−282954.5%−274565.9%
FY15-−101218.6%−100371.2%
FY14-−869.7%−964.9%
FY13--−341.2%
FY12---
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$308.8M
FY24−$398.1M
FY23−$397.3M
FY22−$415.7M
FY21−$308M
FY20−$173.4M
FY19−$156.4M
FY18−$76.5M
FY17−$83.6M
FY16−$45.2M
FY15−$27.5M
FY14−$5.7M
FY13−$671K
FY12-
Returned to shareholdersDividends paid and shares bought back
$0$5M$10M$15M$20MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21$0
FY20$0
FY19$2.5M
FY18$228K
FY17$15.2M
FY16$15.8M
FY15$4.8M
FY14$0
FY13-
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ImmunityBio
  • Healthcare median
−300000%−200000%−100000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearImmunityBioHealthcare median
FY25−310.3%−30.6%
FY24−2805%−47%
FY23−93874.6%−58%
FY22−173875%−80.4%
FY21−37451.8%−71.9%
FY20−36669.6%−62.2%
FY19−7165.2%−46.3%
FY18−204736.2%−49.6%
FY17−214273.3%−45.9%
FY16−274565.9%−36%
FY15−100371.2%−38.4%
FY14−964.9%−35.5%
FY13−341.2%−37.1%
FY12-−29.1%